Edwards Lifesciences EW Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $1.65B+16.7% | $1.57B+13.3% | $1.55B+14.7% | $1.53B+11.9% | $1.41B+6.2% | ||
| $362.6M+20.2% | $343M+17.4% | $345.2M+31.3% | $344.4M+25.0% | $301.6M+5.1% | ||
| $1.29B+15.7% | $1.23B+12.2% | $1.21B+10.7% | $1.19B+8.6% | $1.11B+6.5% | ||
| 78%-0.6pp | 78.1%-0.8pp | 77.8%-2.8pp | 77.5%-2.4pp | 78.7%+0.2pp | ||
| $263.3M+3.4% | $267.7M-1.3% | $280.7M+10.8% | $276.2M+1.6% | $254.6M-0.8% | ||
| $522.2M+12.1% | $602.9M+22.6% | $514.6M+22.1% | $502M+12.2% | $465.7M+8.7% | ||
| $14.2M-25.7% | $14.3M-37.0% | $12.5M+156% | $21.3M— | $19.1M— | ||
| $477.6M+21.0% | $151.1M-51.7% | $307.1M-12.4% | $411.2M+12.2% | $394.8M+13.1% | ||
| 29%+1.0pp | 9.6%-12.9pp | 19.8%-6.1pp | 26.8%+0.1pp | 27.9%+1.7pp | ||
| $33.5M-8.2% | —— | —— | —— | $36.5M+21.4% | ||
| $459M+5.8% | $90.4M-76.8% | $348.4M-13.5% | $400.2M+4.2% | $433.9M+16.9% | ||
| $78.3M+11.4% | $26.2M-41.9% | $56.1M+37.8% | $64.3M+222% | $70.3M+51.8% | ||
| $380.7M+6.3% | $91.2M-76.3% | $291.1M-90.5% | $333.2M-9.0% | $358M+1.7% | ||
| 23.1%-2.2pp | 5.8%-22.0pp | 18.7%-208pp | 21.7%-5.0pp | 25.3%-1.1pp | ||
| $0+100% | $27M-31.3% | -$2M-100% | -$4.4M-540% | -$7.2M-128% | ||
| $0.66+8.2% | $0.16-75.4% | $0.50-90.3% | $0.56-8.2% | $0.61+5.2% | ||
| $0.66+8.2% | $0.16-75.4% | $0.50-90.3% | $0.57-6.6% | $0.61+5.2% | ||
| 580.7M-1.2% | 585.8M-2.3% | 585.7M-2.1% | 587.9M-2.7% | 587.8M-2.7% | ||
| 579.2M-1.3% | 584.8M-2.2% | 584.7M-2.1% | 587M-2.5% | 586.9M-2.4% | ||
| $0.66+6.5% | $0.11-81.0% | $0.50-18.0% | $0.58-4.9% | $0.62+14.8% | ||
| $0.66+6.5% | $0.11-81.0% | $0.50-18.0% | $0.57-6.6% | $0.62+14.8% | ||
| $0.00+100% | $0.05-28.6% | $0.00-100% | -$0.01— | -$0.01-125% | ||
| $37.1M+240% | $208.6M+1,556% | $90.4M+737% | $15.5M+91.4% | $10.9M+22.5% | ||
| $71.5M+2,650% | $3.2M-90.4% | $2.7M-90.3% | -$1.3M-165% | $2.6M-54.4% | ||
| $14.2M-25.7% | $14.3M-37.0% | $12.5M+156% | $21.3M— | $19.1M— | ||
| —— | $4.78M-68.7% | $4.78M-68.7% | $4.78M-68.7% | $4.78M-68.7% | ||
| $0-100% | —— | —— | $4.2M— | $4.2M— | ||
| $1.65B+16.7% | $1.57B+13.3% | $1.55B+14.7% | $1.53B+11.9% | $1.41B+6.2% | ||
| $518.5M+20.2% | $193.8M-45.4% | $346.3M-10.1% | $449.3M+10.6% | $431.4M+11.3% | ||
| 31.5%+0.9pp | 12.3%-13.3pp | 22.3%-6.1pp | 29.3%-0.3pp | 30.5%+1.4pp | ||
| $477.6M+21.0% | $151.1M-51.7% | $307.1M-12.4% | $411.2M+12.2% | $394.8M+13.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Edwards Lifesciences's revenue?
- Edwards Lifesciences (EW) generated $6.3B in revenue over the trailing twelve months, up 14.1% year over year.
- Is Edwards Lifesciences profitable?
- Edwards Lifesciences reported $1.1B in net income over the trailing twelve months, a 17.4% net margin.
- What are Edwards Lifesciences's profit margins?
- Gross margin is 77.9% and operating margin is 21.4%, with a 17.4% net margin.
- What is Edwards Lifesciences's earnings per share?
- Edwards Lifesciences's diluted EPS over the trailing twelve months is $1.88.
- Where does Edwards Lifesciences's income statement data come from?
- Every line is extracted from Edwards Lifesciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
